SSY Group Future Growth

Future criteria checks 4/6

SSY Group is forecast to grow earnings and revenue by 15% and 14% per annum respectively. EPS is expected to grow by 15.1% per annum. Return on equity is forecast to be 20.2% in 3 years.

Key information

15.0%

Earnings growth rate

15.1%

EPS growth rate

Pharmaceuticals earnings growth	10.7%
Revenue growth rate	14.0%
Future return on equity	20.2%
Analyst coverage	Low
Last updated	21 Apr 2024

Recent future growth updates

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

Recent updates

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

Apr 29

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

Apr 15

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Mar 29

SSY Group Limited (HKG:2005) Shares Could Be 26% Below Their Intrinsic Value Estimate

Dec 21

SSY Group (HKG:2005) Has A Pretty Healthy Balance Sheet

Dec 01

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.06

Sep 15

Earnings and Revenue Growth Forecasts

SEHK:2005 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	9,858	2,076	1,772	2,117	2
12/31/2025	8,825	1,844	1,673	1,887	3
12/31/2024	7,583	1,570	899	1,579	4
12/31/2023	6,463	1,319	313	926	N/A
9/30/2023	6,413	1,255	406	965	N/A
6/30/2023	6,363	1,191	499	1,004	N/A
3/31/2023	6,398	1,157	407	869	N/A
12/31/2022	6,434	1,123	316	734	N/A
9/30/2022	6,376	1,101	318	752	N/A
6/30/2022	6,318	1,080	321	769	N/A
3/31/2022	5,838	933	314	733	N/A
12/31/2021	5,357	786	307	696	N/A
9/30/2021	5,139	713	205	605	N/A
6/30/2021	4,921	641	102	514	N/A
3/31/2021	4,591	626	143	509	N/A
12/31/2020	4,261	612	183	505	N/A
9/30/2020	4,177	723	140	558	N/A
6/30/2020	4,093	835	97	611	N/A
3/31/2020	4,364	985	-47	628	N/A
12/31/2019	4,636	1,136	-190	646	N/A
9/30/2019	4,525	1,075	-164	629	N/A
6/30/2019	4,414	1,014	-138	612	N/A
3/31/2019	4,297	963	126	791	N/A
12/31/2018	4,181	912	390	970	N/A
9/30/2018	4,012	867	385	906	N/A
6/30/2018	3,844	822	380	843	N/A
3/31/2018	3,460	743	279	698	N/A
12/31/2017	3,076	665	179	552	N/A
9/30/2017	2,827	616	N/A	676	N/A
6/30/2017	2,577	567	N/A	799	N/A
3/31/2017	2,469	528	N/A	743	N/A
12/31/2016	2,361	490	N/A	686	N/A
9/30/2016	2,315	426	N/A	579	N/A
6/30/2016	2,270	363	N/A	472	N/A
3/31/2016	2,246	383	N/A	517	N/A
12/31/2015	2,222	403	N/A	563	N/A
9/30/2015	2,189	443	N/A	326	N/A
6/30/2015	2,156	482	N/A	89	N/A
3/31/2015	2,124	487	N/A	198	N/A
12/31/2014	2,091	492	N/A	308	N/A
6/30/2014	1,309	402	N/A	613	N/A
3/31/2014	1,516	386	N/A	605	N/A
12/31/2013	1,723	369	N/A	598	N/A
9/30/2013	2,681	386	N/A	594	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2005's forecast earnings growth (15% per year) is above the savings rate (2.2%).

Earnings vs Market: 2005's earnings (15% per year) are forecast to grow faster than the Hong Kong market (11.3% per year).

High Growth Earnings: 2005's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2005's revenue (14% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 2005's revenue (14% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2005's Return on Equity is forecast to be high in 3 years time (20.2%)

SSY Group Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Price target decreased by 7.7% to HK$6.09

Price target increased by 11% to HK$6.19

Price target increased to HK$5.30

Recent updates

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China

Upcoming dividend of HK$0.10 per share

SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year

SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's

SSY Group Limited Provides Update on Product Development

SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year

SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think

Chairman & CEO recently bought HK$2.5m worth of stock

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching

SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China

SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market

SSY Group Limited Receives Approval for Gliclazide Tablet

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China

Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Announces Update on Product Development

SSY Group Limited Provides Update on Product Development

SSY Group Limited Appoints Liu Wenjun as Non-Executive Director

Ssy Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China

SSY Group Limited's (HKG:2005) Price In Tune With Earnings

SSY Group Limited Provides Update on Product Development

Chairman & CEO recently bought HK$4.7m worth of stock

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces Update on Product Development

National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045

SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023

SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China

SSY Group Limited Provides Update on Product Development

SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection

SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China

SSY Group Limited Announces Update on Product Development

Does SSY Group (HKG:2005) Have A Healthy Balance Sheet?

SSY Group Limited Announces Update on Product Development

Upcoming dividend of HK$0.07 per share at 3.5% yield

SSY Group Limited Announces Update on Product Development

Price target decreased by 7.7% to HK$6.09

SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07

SSY Group Limited Provides Update on Product Development

If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity

First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022)

Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023

SSY Group Limited Announces Update on Product Development

SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023

SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China

SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension

Chairman & CEO recently bought HK$8.3m worth of stock

SSY Group Limited Provides Update on Product Development

SSY Group Limited Announces Update on Product Development

Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005)

SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China

SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection

SSY Group Limited Announces Update on Product Development

SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee